Pay in 4 interest-free payments of $6.60 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Key Takeaways Retatrutide is a new triple receptor agonist for GLP-1, GIP, and glucagon receptors to aid appetite regulation and weight loss
Proposed mechanisms include: Reduced estrogen during aggressive weight loss Lower mechanical loading (fewer pounds = less force) Possible GLP-1 effects on calcitonin signaling Bottom line
New or worsening reflux symptoms that don't respond to simple measures should be discussed, as GLP-1 medications are not recommended in severe gastrointestinal disease
Important safety considerations include a boxed warning for thyroid C-cell tumors, contraindication in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and precautions regarding pregnancy (not recommended), reduced oral contraceptive effectiveness, and risks of pancreatitis, gallbladder disease, and acute kidney injury
.jpg)